drugset / Trial / NCT05500482

Vellore Typhoid Vaccine Impact Trial

NCT05500482

RandomizedParallel-groupDouble-blindPrevention

Summary

This cluster randomised trial will examine the impact of introducing TyphiBEV, a typhoid conjugate vaccine licensed in India, on the incidence of typhoid fever in a high burden urban setting in South India.

Timeline

Start
2023-05-01
Primary completion
2026-01-31
Completion
2026-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject TYPHIBEV Vaccine 0.5 ml Intramuscular

Indications